{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:23:30Z","timestamp":1781375010389,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["960570"],"award-info":[{"award-number":["960570"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.remnie.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T16:23:35Z","timestamp":1631463815000},"page":"239-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study"],"prefix":"10.1016","volume":"41","author":[{"given":"Soroush","family":"Zarehparvar Moghadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasemali","family":"Divband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shakeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2021.05.005_bib0005","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00259-018-4067-3","article-title":"(68)Ga-PSMA PET\/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients","volume":"45","author":"Caroli","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2021.05.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180308","article-title":"Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen","volume":"91","author":"Kulkarni","year":"2018","journal-title":"Br J Radiol."},{"key":"10.1016\/j.remnie.2021.05.005_bib0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","article-title":"Current status of theranostics in prostate cancer","volume":"45","author":"Virgolini","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2021.05.005_bib0020","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"(177)Lu-PSMA radioligand therapy for prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2021.05.005_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.remnie.2021.05.005_bib0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2021.05.005_bib0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS259","article-title":"Vision: an international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Sartor","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2021.05.005_bib0040","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2021.05.005_bib0045","first-page":"2","article-title":"The iranian society of nuclear medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA","volume":"26","author":"Ahmadzadehfar","year":"2018","journal-title":"Iran J Nucl Med."},{"key":"10.1016\/j.remnie.2021.05.005_bib0050","unstructured":"U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute, NCCN Clinical Practice Guidelines in Oncology (NCCN common terminology criteria for adverse events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Updated March 27, 2020. Accessed April 13, 2020."},{"key":"10.1016\/j.remnie.2021.05.005_bib0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00259-017-3877-z","article-title":"Delayed response after repeated 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2021.05.005_bib0060","unstructured":"Therneau T.M., Lumley T., Atkinson E. Survival analysis. https:\/\/cran.r-project.org\/web\/packages\/survival\/survival.pdf. Updated April 10, 2020. Accessed April 13, 2020."},{"key":"10.1016\/j.remnie.2021.05.005_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2021.05.005_bib0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"Am J Roentgenol."},{"key":"10.1016\/j.remnie.2021.05.005_bib0075","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.remnie.2021.05.005_bib0080","doi-asserted-by":"crossref","first-page":"W2","DOI":"10.2214\/AJR.19.22271","article-title":"Fact checking on 177Lu-PSMA nephrotoxicity","volume":"215","author":"Aryana","year":"2020","journal-title":"Am J Roentgenol."},{"key":"10.1016\/j.remnie.2021.05.005_bib0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"l. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2021.05.005_bib0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of 177Lu\u2010PSMA\u2010617 theranostic treatment vs cabazitaxel in progressive metastatic castration\u2010resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int."},{"key":"10.1016\/j.remnie.2021.05.005_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-25019-1","article-title":"A temporal examination of platelet counts as a predictor of prognosis in lung, prostate, and colon cancer patients","volume":"8","author":"Sylman","year":"2018","journal-title":"Sci Rep."},{"key":"10.1016\/j.remnie.2021.05.005_bib0100","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2021.05.005_bib0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808921001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808921001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:47:08Z","timestamp":1778960828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808921001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2253808921001063"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2021.05.005","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2021.03.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}